Morgan Stanley Lowers ResMed Price Target Citing Philips Competition

Key Facts

1Morgan Stanley reduced its price target for ResMed to $286 from $310 while maintaining an Overweight rating.

2The price target cut is attributed to anticipated market competition, particularly from Philips re-entering the market.

Morgan Stanley has revised its price target for ResMed (RMD) downward to $286 from $310, while maintaining an Overweight rating on the stock. The adjustment, representing an approximately 7.7% reduction, is primarily driven by anticipated market competition as Philips prepares to re-enter the sector. Analysts suggest that the return of major competitors could create headwinds for ResMed's market dominance in the near term. Despite the lower price target, Morgan Stanley remains optimistic about the company's long-term growth prospects and fundamental strength. Investors are closely monitoring how the shifting competitive landscape will impact ResMed's margins and market share. This revision reflects a tactical caution regarding valuation amid evolving industry dynamics.